Document is current
Any future updates will be listed below
-
Authors
Shaw, Stephen M.
Middleton, Jenny
Wigglesworth, Kim
Charlemagne, Amber
Schulz, Oliver
Glossop, Melanie S.
Whalen, Giles F.
Old, Robert
Westby, Mike
Pickford, Chris
Tabakman, Rinat
Carmi-Levy, Irit
Vainstein, Abi
Sorani, Ella
Zur, Arik A. https://orcid.org/0000-0003-2776-9218
Kristian, Sascha A.
- License Information
-
More Information
Article History
Received: 1 September 2019
Accepted: 5 December 2019
First Online: 19 December 2019
Ethics approval and consent to participate
: Human blood was sourced as non-clinical component leukocyte cones from the NHS Blood and Transplant government agency in the United Kingdom, with valid and appropriate donor consent for research purposes. All experimental procedures for α1,3GT<sup>−/−</sup> mice were reviewed and approved by the University of Massachusetts, Worcester IACUC. OT-IxRag1<sup>−/−</sup> mice were bred at The Francis Crick Institute, London, UK under specific pathogen-free conditions in accordance with the national and institutional guidelines for animal care and approval by The Francis Crick Institute Animal Ethics Committee and by the Home Office, United Kingdom.
: Not applicable.
: All of the authors are or were employees, have or had executive roles and/or are consultants to, and may have stocks or shares of Agalimmune Ltd. or BioLineRx, and may hold patents related to the described work. Several of the authors are or were involved in efforts to develop AGI-134 as cancer immunotherapy. AGI-134 is currently in Phase 1/2a clinical trials in the United Kingdom and Israel with BioLineRx as sponsor.
